Skip to main content
. 2019 Aug 8;7:212. doi: 10.1186/s40425-019-0663-4

Fig. 1.

Fig. 1

Pembrolizumab ADA patient analysis. ADA, antidrug antibody; NAb, neutralizing antibody; non-TE, non–treatment-emergent; TE, treatment-emergent